ProShare Advisors’s Ariad Pharmaceuticals Inc ARIA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q1 | – | Sell |
-156,720
| Closed | -$1.95M | – | 1735 |
|
|
2016
Q4 | $1.95M | Buy |
156,720
+15,145
| +11% | +$182K | 0.02% | 558 |
|
|
2016
Q3 | $1.94M | Sell |
141,575
-22,593
| -14% | -$227K | 0.03% | 506 |
|
|
2016
Q2 | $1.21M | Buy |
164,168
+2,914
| +2% | +$21.9K | 0.02% | 659 |
|
|
2016
Q1 | $1.03M | Sell |
161,254
-15,346
| -9% | -$86K | 0.01% | 691 |
|
|
2015
Q4 | $1.1M | Buy |
176,600
+16,552
| +10% | +$109K | 0.01% | 699 |
|
|
2015
Q3 | $935K | Sell |
160,048
-11,743
| -7% | -$90.5K | 0.01% | 694 |
|
|
2015
Q2 | $1.42M | Sell |
171,791
-10,889
| -6% | -$96.3K | 0.02% | 628 |
|
|
2015
Q1 | $1.5M | Buy |
182,680
+23,299
| +15% | +$172K | 0.02% | 652 |
|
|
2014
Q4 | $1.09M | Sell |
159,381
-2,459
| -2% | -$15.4K | 0.01% | 811 |
|
|
2014
Q3 | $874K | Sell |
161,840
-39,098
| -19% | -$228K | 0.01% | 1120 |
|
|
2014
Q2 | $1.28M | Buy |
200,938
+51,269
| +34% | +$353K | 0.02% | 1047 |
|
|
2014
Q1 | $1.21M | Buy |
149,669
+61,855
| +70% | +$482K | 0.02% | 1139 |
|
|
2013
Q4 | $599K | Buy |
87,814
+17,382
| +25% | +$93.8K | 0.01% | 1050 |
|
|
2013
Q3 | $1.3M | Buy |
70,432
+30,062
| +74% | +$584K | 0.03% | 674 |
|
|
2013
Q2 | $706K | Buy |
+40,370
| New | +$716K | 0.01% | 1073 |
|
Other funds holding ARIA
ProShare Advisors's ARIA Position: Q1 2017 in Review
ProShare Advisors sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 156,720 shares — an estimated $1.95M sold.
ProShare Advisors first reported a position in ARIA in Q2 2013 and held it in 15 quarters. The position peaked at $1.95M in Q4 2016. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.
- ProShare Advisors reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
- ProShare Advisors sold 156,720 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $1.95M.
- ProShare Advisors first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 15 quarters.
- ProShare Advisors's Ariad Pharmaceuticals Inc position peaked at $1.95M in Q4 2016.
- 1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.
Based on ProShare Advisors's 13F filing for Q1 2017, filed 25 Apr 2017.